DGM
RLAY icon

Darwin Global Management’s Relay Therapeutics RLAY Stock Holding History

Darwin Global Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-119,775
Closed -$4.38M – 17
2021
Q2 		$4.38M Sell
119,775
-662,696
-85% -$21.8M 0.71% 11
2021
Q1 		$27.1M Buy
+782,471
New +$34M 5.3% 4

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Darwin Global Management's RLAY Position: Q3 2021 in Review

Darwin Global Management sold out of Relay Therapeutics (RLAY) in Q3 2021, closing a stake of 119,775 shares — an estimated $4.38M sold.

Darwin Global Management first reported a position in RLAY in Q1 2021 and held it in 2 quarters. The position peaked at $27.1M in Q1 2021. 132 funds tracked by Wall St. Rank hold RLAY as of Q3 2021.

  • Darwin Global Management reported no remaining Relay Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Darwin Global Management sold 119,775 Relay Therapeutics shares in Q3 2021, an estimated $4.38M.
  • Darwin Global Management first reported a position in Relay Therapeutics in Q1 2021 and held it in 2 quarters.
  • Darwin Global Management's Relay Therapeutics position peaked at $27.1M in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2021.

Based on Darwin Global Management's 13F filing for Q3 2021, filed 15 Nov 2021.